Appointed by Governor: Marco T. A. Priolo; Samantha M. Smith; Allison L. Taylor, Esq.; Sanford K. Walters
Appointed by Senate President: Delores G. Kelley; Christopher R. West.
Appointed by House Speaker: Bonnie L. Cullison; Kirill Reznik.
Appointed by Senate President & House Speaker: Donna M. Carris; Vincent DeMarco, J.D.; Lori Doyle; Jamal Lee; Deborah R. Rivkin.
Representing Maryland Hospital Association: Robert O. Atlas, M.D.
Representing MedChi: Stephen J. Rockower, M.D.
Ex officio: Carolyn A. Quattrocki, designee of Attorney General; Dennis R. Schrader, Secretary of Health; David J. Cooney, designee of Maryland Insurance Commissioner.
Staff: Laura E. Goodman (410) 767-5683; e-mail: laura.goodman@maryland.gov
c/o Office of Secretary, Maryland Department of Health
Herbert R. O'Conor State Office Building, 201 West Preston St., Baltimore, MD 21201 - 2399
Staff: Michael Paddy (410) 468-2408; e-mail: michael.paddy@maryland.gov
c/o Maryland Insurance Commissioner, Maryland Insurance Administration
St. Paul Plaza, Suite 2700
200 St. Paul Place, Baltimore, MD 21202 - 2272
St. Paul Plaza, 200 St. Paul Place, Baltimore, Maryland, July 2007. Photo by Diane F. Evartt.
In June 2017, the Maryland Health Insurance Coverage Protection Commission was authorized by the General Assembly (Chapter 17, Acts of 2017).
Changes and proposed changes to the federal Patient Protection and Affordable Care Act, the Maryland Children's Health Program, Medicaid, Medicare, and the Maryland All-Payer Model are monitored by the Commission. Their impact is assessed by the Commission, which makes recommendations on how to ensure that Maryland residents have access to affordable health coverage.
The Commission also assesses the adverse effects on State residents, public health, and the economy resulting from the loss of health coverage through changes to the federal Patient Protection and Affordable Care Act. Moreover, it estimates the costs of such changes to Maryland and its residents, and examines measures to prevent or mitigate their adverse effects on the Maryland Children's Health Program, Medicaid, Medicare, and the Maryland All-Payer Model.
In April 2018, the Commission further was to undertake a study of options for ensuring stability in the individual and group health insurance markets. Commission findings and recommendations will be included in its 2019 annual report (Chapters 37 & 38, Acts of 2018).
Additionally, in October 2019, the Commission was charged to study and make recommendations on whether the State Reinsurance Program should be extended after December 2023, and if so, how it would be funded (Chapters 597 & 598, Acts of 2019).
Authorization for the Commission originally was to end June 30, 2020, but was extended through June 30, 2023 (Chapters 417 & 418, Acts of 2019).
In June 2019, the Maryland Health Insurance Coverage Protection Commission convened the Health Insurance Consumer Protections Work Group at the request of the General Assembly (Chapters 417 & 418, Acts of 2019).
The Work Group is monitoring the appeal of the decision of the U.S. District Court for the Northern District of Texas in Texas v. United States regarding the federal Patient Protection and Affordable Care Act and the implications of the decision for Maryland. Further, the Work Group will monitor the enforcement of the Act by the U.S. Department of Health and Human Services. Finally, the Work Group is to determine the most effective means for ensuring Maryland consumers can both get and keep quality health insurance.
© Copyright Maryland State Archives